Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2012, Article ID 735392, 9 pages
http://dx.doi.org/10.1155/2012/735392
Clinical Study

HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era

1Division of Hematology, St. Paul's Hospital and the University of British Columbia, Vancouver, BC, Canada V6T 1Z4
2Division of Hematology, St. Michael's Hospital and the University of Toronto, Toronto, ON, Canada M5S 1A1
3Division of Hematology, Sunnybrook Health Sciences Centre and the University of Toronto, Toronto, ON, Canada M5S 1A1
4Leukemia/BMT Program of British Columbia, BC Cancer Agency, Vancouver, BC, Canada V5Z 1M9
5British Columbia Centre for Excellence in HIV/AIDS (CFE), St. Paul's Hospital and the University of British Columbia, Vancouver, BC, Canada V6T 1Z4
6AIDS Research Program, St. Paul's Hospital and the University of British Columbia, Vancouver, BC, Canada V6T 1Z4

Received 11 June 2011; Accepted 6 September 2011

Academic Editor: Jeremy S. Abramson

Copyright © 2012 J. A. Rodrigo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. L. Hecht and J. C. Aster, “Molecular biology of Burkitt's lymphoma,” Journal of Clinical Oncology, vol. 18, no. 21, pp. 3707–3721, 2000. View at Google Scholar · View at Scopus
  2. A. S. Perkins and J. W. Friedberg, “Burkitt lymphoma in adults,” Hematology/American Society of Hematology. Education Program, pp. 341–348, 2008. View at Google Scholar · View at Scopus
  3. L. Leoncini, M. Raphael, H. Stein, N. L. Harris, E. Jaffe, and P. M. Kluin, “Burkitt lymphoma,” in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, S. Swerdlow, E. Campo, and N. Harris, Eds., pp. 262–264, The International Agency for Research on Cancer, Lyon , France, 4th edition, 2004. View at Google Scholar
  4. M. Guech-Ongey, E. P. Simard, W. F. Anderson et al., “AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology?” Blood, vol. 116, no. 25, pp. 5600–5604, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. V. S. Blinder, A. Chadburn, R. R. Furman, S. Mathew, and J. P. Leonard, “Review: improving outcomes for patients with Burkitt lymphoma and HIV,” AIDS Patient Care and STDs, vol. 22, no. 3, pp. 175–187, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Antinori, A. Cingolani, L. Alba et al., “Better response to chemotherapy and prolonged survival in aids-related lymphomas responding to highly active antiretroviral therapy,” AIDS, vol. 15, no. 12, pp. 1483–1491, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Besson, A. Goubar, J. Gabarre et al., “Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy,” Blood, vol. 98, no. 8, pp. 2339–2344, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. K. U. Chow, P. S. Mitrou, K. Geduldig, E. B. Helm, D. Hoelzer, and H. R. Brodt, “Changing incidence and survival in patients with AIDS-related non-Hodgkin's lymphomas in the era of highly active antireroviral therapy (HAART),” Leukemia and Lymphoma, vol. 41, no. 1-2, pp. 105–116, 2001. View at Google Scholar · View at Scopus
  9. O. Kirk, C. Pedersen, A. Cozzi-Lepri et al., “Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy,” Blood, vol. 98, no. 12, pp. 3406–3412, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. G. V. Matthews, M. Bower, S. Mandalia, T. Powles, M. R. Nelson, and B. G. Gazzard, “Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy,” Blood, vol. 96, no. 8, pp. 2730–2734, 2000. View at Google Scholar · View at Scopus
  11. J.-T. Navarro, J.-M. Ribera, A. Oriol, C. Tural, F. Millá, and E. Feliu, “Improved outcome of AIDS-related lymphoma in patients with virologic response to highly active antiretroviral therapy,” Journal of Acquired Immune Deficiency Syndromes, vol. 32, no. 3, pp. 347–348, 2003. View at Publisher · View at Google Scholar
  12. E. Vaccher, G. di Gennaro, O. Shioppa et al., “Highly active antiretroviral therapy (HAART) significantly improves disease free survival (DFS) in patients (pts) with HIV-related Non-Hodgkin's Lymphoma (HIV-NHL) treated with chemotherapy (CT),” Proceedings of the American Society of Clinical Oncology, vol. 20, no. 2, article 294a, 2001. View at Google Scholar
  13. B. Coiffier, E. Lepage, J. Brière et al., “Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma,” The New England Journal of Medicine, vol. 346, no. 4, pp. 235–242, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. L. H. Sehn, J. Donaldson, M. Chhanabhai et al., “Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia,” Journal of Clinical Oncology, vol. 23, no. 22, pp. 5027–5033, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. D. A. Thomas, S. Faderl, S. O'Brien et al., “Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia,” Cancer, vol. 106, no. 7, pp. 1569–1580, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Ezzat, D. Filipenko, L. Vickars et al., “Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy,” HIV Clinical Trials, vol. 8, no. 3, pp. 132–144, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. L. D. Kaplan, J. Y. Lee, R. F. Ambinder et al., “Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010,” Blood, vol. 106, no. 5, pp. 1538–1543, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Spina, U. Jaeger, J. A. Sparano et al., “Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials,” Blood, vol. 105, no. 5, pp. 1891–1897, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Boué, J. Gabarre, C. Gisselbrecht et al., “Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 24, no. 25, pp. 4123–4128, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. J. A. Sparano, J. Y. Lee, L. D. Kaplan et al., “Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma,” Blood, vol. 115, no. 15, pp. 3008–3016, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. S. B. Murphy, W. P. Bowman, and M. Abromowitch, “Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine,” Journal of Clinical Oncology, vol. 4, no. 12, pp. 1732–1739, 1986. View at Google Scholar
  22. D. A. Thomas, J. Cortes, S. O'Brien et al., “Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia,” Journal of Clinical Oncology, vol. 17, no. 8, pp. 2461–2470, 1999. View at Google Scholar · View at Scopus
  23. G. Todeschini, C. Tecchio, D. Degani et al., “Eighty-one percent event-free survival in advanced Burkitt's lymphoma/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol,” Annals of Oncology, vol. 8, no. 1, pp. S77–S81, 1997. View at Google Scholar · View at Scopus
  24. L. D. Kaplan, D. J. Straus, M. A. Testa et al., “Low-dose compared with standard-dose m-BACOD chemotherapy for non- Hodgkin's lymphoma associated with human immunodeficiency virus infection,” The New England Journal of Medicine, vol. 336, no. 23, pp. 1641–1648, 1997. View at Publisher · View at Google Scholar
  25. S. T. Lim, R. Karim, B. N. Nathwani, A. Tulpule, B. Espina, and A. M. Levine, “AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy,” Journal of Clinical Oncology, vol. 23, no. 19, pp. 4430–4438, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Cortes, D. Thomas, A. Rios et al., “Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia,” Cancer, vol. 94, no. 5, pp. 1492–1499, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Krishnan, A. Molina, J. Zaia et al., “Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas,” Blood, vol. 105, no. 2, pp. 874–878, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. J. W. Sweetenham, R. Pearce, G. Taghipour, D. Biaise, C. Gisselbrecht, and A. H. Goldstone, “Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma—outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European group for blood and marrow transplantation,” Journal of Clinical Oncology, vol. 14, no. 9, pp. 2465–2472, 1996. View at Google Scholar · View at Scopus
  29. I. Magrath, M. Adde, A. Shad et al., “Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen,” Journal of Clinical Oncology, vol. 14, no. 3, pp. 925–934, 1996. View at Google Scholar · View at Scopus
  30. Chemotherapy Protocols, Lymphoma & Myeloma, 2011, http://www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Lymphoma/default.htm.
  31. C. C. J. Carpenter, M. A. Fischl, S. M. Hammer et al., “Antiretroviral therapy for HIV infection in 1996 recommendations of an international panel. International AIDS Society-USA,” JAMA, vol. 276, no. 2, pp. 146–154, 1996. View at Google Scholar
  32. J. Pelgrims, F. De Vos, J. Van Den Brande, D. Schrijvers, A. Prové, and J. B. Vermorken, “Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature,” British Journal of Cancer, vol. 82, no. 2, pp. 291–294, 2000. View at Google Scholar · View at Scopus
  33. A. R. Turner, C. D. Duong, and D. J. Good, “Methylene blue for the treatment and prophylaxis of ifosfamide-induced encephalopathy,” Clinical Oncology, vol. 15, no. 7, pp. 435–439, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. F. Boue, J. Gabarre, C. Gisselbrecht et al., “CHOP chemotherapy plus rituximab in HIV patients with high grade lymphoma- results of an ANRS trial,” Blood, vol. 100, no. 11, abstract 1824, 2002. View at Google Scholar
  35. A. Krishnan, A. Molina, J. Zaia et al., “Autologous stem cell transplantation for HIV-associated lymphoma,” Blood, vol. 98, no. 13, pp. 3857–3859, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Oriol, J. M. Ribera, J. Bergua et al., “High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients,” Cancer, vol. 113, no. 1, pp. 117–125, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Oriol, J. M. Ribera, J. Esteve et al., “Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study,” Haematologica, vol. 88, no. 4, pp. 445–453, 2003. View at Google Scholar · View at Scopus
  38. E. S. Wang, D. J. Straus, J. Teruya-Feldstein et al., “Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma,” Cancer, vol. 98, no. 6, pp. 1196–1205, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Montoto, J. Wilson, K. Shaw et al., “Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma,” AIDS, vol. 24, no. 6, pp. 851–856, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Noy, L. Kaplan, and J. Lee, “Efficacy and tolerability of modified dose intensive R- CODOX-M/IVAC for HIV-associated burkitt (BL) (AMC 048),” Annals of Oncology, vol. 22, supplement 4, 2011, abstract 342. View at Google Scholar
  41. K. Dunleavy, S. Pittaluga, A. S. Wayne et al., “MYC + aggressive-B-cell lymphomas: novel therapy of untreated burkitt lymphoma (BL) and MYC + diffuse large B-cell lymphoma (DLBCL) with DA-EPOCH-R,” Annals of Oncology, vol. 22, supplement 4, 2011, abstract 071. View at Google Scholar
  42. S. G. Mohamedbhai, K. Sibson, T. Marafioti et al., “Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%,” British Journal of Haematology, vol. 152, no. 2, pp. 175–181, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. N. Macpherson, D. Lesack, R. Klasa et al., “Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation,” Journal of Clinical Oncology, vol. 17, no. 5, pp. 1558–1567, 1999. View at Google Scholar · View at Scopus
  44. K. Chaiwatanatorn, N. Lee, A. Grigg, R. Filshie, and F. Firkin, “Delayed-onset neutropenia associated with rituximab therapy,” British Journal of Haematology, vol. 121, no. 6, pp. 913–918, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. S. E. Motl and R. C. Baskin, “Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lymphoma: case report and literature review,” Pharmacotherapy, vol. 25, no. 8, pp. 1151–1155, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. A. G. Marcelin, L. Aaron, C. Mateus et al., “Rituximab therapy for HIV-associated Castleman disease,” Blood, vol. 102, no. 8, pp. 2786–2788, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. J. T. Navarro, N. Lloveras, J. M. Ribera, A. Oriol, J. L. Mate, and E. Feliu, “The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy,” Haematologica, vol. 90, no. 5, pp. 704–706, 2005. View at Google Scholar · View at Scopus